ENGN CIK: 1980845

enGene Therapeutics Inc.

  • Canada
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY22
FY23
FY24
FY25
FY22 – FY25

Assets

(positive)
Change from FY22 to FY25
millions USD
FY22:
22.6
FY23:
85.4
FY24:
247
FY25:
201
(positive)
Change from FY22 to FY25
millions USD
FY22:
1.33
FY23:
1.52
FY24:
63.8
FY25:
20.1
Total assets
Change from FY22 to FY25
millions USD
FY22:
23.9
FY23:
87.0
FY24:
311
FY25:
221

Liabilities & Equity

(negative)
Change from FY22 to FY25
millions USD
FY22:
5.10
FY23:
5.26
FY24:
14.7
FY25:
32.0
(negative)
Change from FY22 to FY25
millions USD
FY22:
42.3
FY23:
9.22
FY24:
23.9
FY25:
21.8
(positive)
Change from FY22 to FY25
millions USD
FY22:
−76.6
FY23:
72.5
FY24:
273
FY25:
168
Total liabilities & equity
Change from FY23 to FY25
millions USD
FY22:
–
FY23:
87.0
FY24:
311
FY25:
221

All amounts in millions USD Data source:SEC EDGAR